Reduction of CD19 autoimmunity marker on B cells of paediatric SLE patients through repressing PU.1/TNF-α/BAFF axis pathway by miR-155

References

• Aringer M, Smolen JS. 2003. SLE – Complex cytokine effects in a complex autoimmune disease: Tumor necrosis factor in systemic lupus erythematosus. Arthritis Res Ther 5:172–177.
   Web of Science ®Google Scholar
• Aringer M, Smolen JS. 2008. Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. Expert Opin Drug Saf 7:411–419.
   PubMed Web of Science ®Google Scholar
• Assi LK, Wong SH, Ludwig A, Raza K, Gordon C, Salmon M, Lord JM, Scheel-Toellner D. 2007. Tumor necrosis factor alpha activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint. Arthritis Rheum 56:1776–1786.
   PubMed Web of Science ®Google Scholar
• Calame K. 2007. MicroRNA-155 function in B Cells. Immunity 27:825–827.
   PubMed Web of Science ®Google Scholar
• Carotta S, Dakic A, D’Amico A, Pang SH, Greig KT, Nutt SL, Wu L. 2010. The transcription factor PU.1 controls dendritic cell development and Flt3 cytokine receptor expression in a dose-dependent manner. Immunity 32:628–641.
   PubMed Web of Science ®Google Scholar
• Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, Croce CM. 2006. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA 103:7024–7029.
   PubMed Web of Science ®Google Scholar
• Dai R, Zhang Y, Khan D, Heid B, Caudell D, Crasta O, Ahmed SA. 2010. Identification of a common lupus disease-associated microRNA expression pattern in three different murine models of lupus. PLoS One 5:e14302.
   PubMed Web of Science ®Google Scholar
• Dozmorov MG, Wren JD, Alarcon-Riquelme ME. 2014. Epigenomic elements enriched in the promoters of autoimmunity susceptibility genes. Epigenetics 9:276–285.
   PubMed Web of Science ®Google Scholar
• Fukai T, Nishiyama C, Kanada S, Nakano N, Hara M, Tokura T, Ikeda S, et al. 2009. Involvement of PU.1 in the transcriptional regulation of TNF-alpha. Biochem Biophys Res Commun 388:102–106.
   PubMed Web of Science ®Google Scholar
• Gabay C, Cakir N, Moral F, Roux-Lombard P, Meyer O, Dayer JM, Vischer T, et al. 1997. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 24:303–308.
   PubMed Web of Science ®Google Scholar
• Garo LP, Murugaiyan G. 2016. Contribution of MicroRNAs to autoimmune diseases. Cell Mol Life Sci 73:2041–2051.
   PubMed Web of Science ®Google Scholar
• Gomez D, Correa PA, Gómez LM, Cadena J, Molina JF, Anaya JM. 2004. Th1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor alpha protective? Semin Arthritis Rheum 33:404–413.
   PubMed Web of Science ®Google Scholar
• Hase H, Kanno Y, Kojima M, Hasegawa K, Sakurai D, Kojima H, Tsuchiya N, et al. 2004. BAFF/BLyS can potentiate B-cell selection with the B-cell coreceptor complex. Blood 103:2257–2265.
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Fujimoto M, Poe JC, Steeber DA, Lowell CA, Tedder TF. 2001. A CD19-dependent signaling pathway regulates autoimmunity in Lyn-deficient mice. J Immunol 167:2469–2478.
   PubMed Web of Science ®Google Scholar
• Hikami K, Kawasaki A, Ito I, Koga M, Ito S, Hayashi T, Matsumoto I, et al. 2011. Association of a functional polymorphism in the 3'-untranslated region of SPI1 with systemic lupus erythematosus. Arthritis Rheum 63:755–763.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. 1997. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725.
   PubMed Web of Science ®Google Scholar
• Inaoki M, Sato S, Weintraub BC, Goodnow CC, Tedder TF. 1997. CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes. J Exp Med 186:1923–1931.
   PubMed Web of Science ®Google Scholar
• Ittah M, Miceli-Richard C, Eric Gottenberg J, Lavie F, Lazure T, Ba N, Sellam J, et al. 2006. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. Arthritis Res Ther 8:R51.
   PubMed Web of Science ®Google Scholar
• Iwasaki H, Somoza C, Shigematsu H, Duprez EA, Iwasaki-Arai J, Mizuno S, Arinobu Y, et al. 2005. Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation. Blood 106:1590–1600.
   PubMed Web of Science ®Google Scholar
• Jacob CO. 1992. Tumor necrosis factor alpha in autoimmunity: Pretty girl or old witch? Immunol Today 13:122–125.
   PubMedGoogle Scholar
• Javierre BM, Fernandez AF, Richter J, Al-Shahrour F, Martin-Subero JI, Rodriguez-Ubreva J, Berdasco M, et al. 2010. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res 20:170–179.
   PubMed Web of Science ®Google Scholar
• Khanna S, Pal H, Pandey RM, Handa R. 2004. The relationship between disease activity and quality of life in systemic lupus erythematosus. Rheumatology (Oxford) 43:1536–1540.
   PubMed Web of Science ®Google Scholar
• Lashine YA, Salah S, Aboelenein HR, Abdelaziz AI. 2014. Correcting the expression of miRNA 155 represses PP2Ac and enhances the release of IL-2 in PBMCs of juvenile SLE patients. Lupus 24:240–247.
   PubMed Web of Science ®Google Scholar
• Lee GH, Lee J, Lee JW, Choi WS, Moon EY. 2013. B cell activating factor-dependent expression of vascular endothelial growth factor in MH7A human synoviocytes stimulated with tumor necrosis factor-alpha. Int Immunopharmacol 17:142–147.
   PubMed Web of Science ®Google Scholar
• Lin CC, Liu LZ, Addison JB, Wonderlin WF, Ivanov AV, Ruppert JM. 2011. A KLF4-miRNA-206 autoregulatory feedback loop can promote or inhibit protein translation depending upon cell context. Mol Cell Biol 31:2513–2527.
   PubMed Web of Science ®Google Scholar
• Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL. 1999. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190:1697–1710.
   PubMed Web of Science ®Google Scholar
• McKercher SR, Torbett BE, Anderson KL, Henkel GW, Vestal DJ, Baribault H, Klemsz M, et al. 1996. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J 15:5647–5658.
   PubMed Web of Science ®Google Scholar
• Mei HE, Schmidt S, Dorner T. 2012. Rationale of anti-CD19 immunotherapy: An option to target autoreactive plasma cells in autoimmunity. Arthritis Res Ther 14(Suppl 5):S1.
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, et al. 2011. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 377:721–731.
   PubMed Web of Science ®Google Scholar
• Niwa Y, Nishiyama C, Nakano N, Kamei A, Kato H, Kanada S, Ikeda S, et al. 2008. Opposite effects of PU.1 on mast cell stimulation. Biochem Biophys Res Commun 375:95–100.
   PubMed Web of Science ®Google Scholar
• Rasmussen TK, Andersen T, Bak RO, Yiu G, Sørensen CM, Pedersen KS, Mikkelsen JG, et al. 2015. Overexpression of microRNA-155 increases IL-21 mediated STAT3 signaling and IL-21 production in systemic lupus erythematosus. Arthritis Res Ther 17:154.
   PubMed Web of Science ®Google Scholar
• Sabry A, Sheashaa H, El-Husseini A, Mahmoud K, Eldahshan KF, George SK, Abdel-Khalek E, et al. 2006. Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: Its correlation with disease activity. Cytokine 35:148–153.
   PubMed Web of Science ®Google Scholar
• Sato S, Fujimoto M, Hasegawa M, Takehara K. 2004. Altered blood B lymphocyte homeostasis in systemic sclerosis: Expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 50:1918–1927.
   PubMed Web of Science ®Google Scholar
• Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. 2000. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 165:6635–6643.
   PubMed Web of Science ®Google Scholar
• Simpson LJ, Ansel KM. 2015. MicroRNA regulation of lymphocyte tolerance and autoimmunity. J Clin Invest 125:2242–2249.
   PubMed Web of Science ®Google Scholar
• Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, Roschke V, et al. 2003. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations. Arthritis Rheum 48:3475–3486.
   PubMed Web of Science ®Google Scholar
• Studnicka-Benke A, Steiner G, Petera P, Smolen JS. 1996. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 35:1067–1074.
   PubMedGoogle Scholar
• Thai TH, Patterson HC, Pham DH, Kis-Toth K, Kaminski DA, Tsokos GC. 2013. Deletion of microRNA-155 reduces autoantibody responses and alleviates lupus-like disease in the Fas(lpr) mouse. Proc Natl Acad Sci USA 110:20194–20199.
   PubMed Web of Science ®Google Scholar
• Vigorito E, Perks KL, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S, Das PP, et al. 2007. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity 27:847–859.
   PubMed Web of Science ®Google Scholar
• Wang G, Tam LS, Kwan BC, Li EK, Chow KM, Luk CC, Li PK, Szeto CC. 2012. Expression of miR-146a and miR-155 in the urinary sediment of systemic lupus erythematosus. Clin Rheumatol 31:435–440.
   PubMed Web of Science ®Google Scholar
• Wang G, Tam LS, Li EK, Kwan BC, Chow KM, Luk CC, Li PK, Szeto CC. 2010. Serum and urinary cell-free MiR-146a and MiR-155 in patients with systemic lupus erythematosus. J Rheumatol 37:2516–2522.
   PubMed Web of Science ®Google Scholar
• Wang H, Peng W, Ouyang X, Li W, Dai Y. 2012. Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus. Transl Res 160:198–206.
   PubMed Web of Science ®Google Scholar
• Wang YZ, Tian FF, Yan M, Zhang JM, Liu Q, Lu JY, Zhou WB, et al. 2014. Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis. Clin Exp Immunol 176:207–221.
   PubMed Web of Science ®Google Scholar
• Xiong W, Lahita RG. 2011. Novel treatments for systemic lupus erythematosus. Ther Adv Musculoskelet Dis 3:255–266.
   PubMedGoogle Scholar
• Zhang J, Roschke V, Baker KP, Wang Z, Alarcón GS, Fessler BJ, Bastian H, et al. 2001. Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166:6–10.
   PubMed Web of Science ®Google Scholar